Development of Dual V1a/V2 Antagonists Containing Triazolobenzazepine Scaffold

Gábor Varró,Éva Bozó,Krisztina Vukics,Ferenc Baska,Gábor Szántó,Balázs Krámos,Katalin,Domány-Kovács,Krisztina Szondiné Kordás,Mónika Vastag,Ildikó Magdó,Imre Bata
DOI: https://doi.org/10.1016/j.ejmech.2024.117069
IF: 7.088
2024-11-30
European Journal of Medicinal Chemistry
Abstract:The development of a dual V1a/V2 antagonist compound is a complex and challenging task. Conivaptan is up to now the only known V1a/V2 antagonist which was approved for the treatment of euvolemic hyponatremia. Previously, we reported RGH-122 , a novel selective V1a antagonist compound. Herein, we describe several promising dual antagonist compounds, which are derived from RGH-122 by using modifications in its tail region. These modifications can result in excellent binding affinity on both V1a and V2 receptors.
chemistry, medicinal
What problem does this paper attempt to address?